This document discusses opportunities in wound care for Client X. It provides background on the complex and costly nature of wound care, particularly chronic wounds which affect millions of patients annually. The proposal suggests identifying disruptive areas through qualitative research and ideation to determine unmet needs, current and future trends, and technologies that could help address these needs and create value for Client X in advanced wound management.

1.
0
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
CLIENT
X
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care

2.
1
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
DATE
Mr.
X
Y
Position
Advanced
Wound
Care
CLIENT
X
Location
Location
United Kingdom
Dear
Mr.
Y,
Per
our
conversation,
Harrison
Hayes
is
pleased
to
present
a
research
proposal
that
will
focus
on
making
specific
recommendations
for
CLIENT
X’s
unmet
needs
and
to
identify
unmet
needs
and
new
opportunities
that
would
create
value
generation
to
support
the
Advanced
Wound
Management
sector.
In
this
proposal,
we
present
a
review
of
the
objectives,
scope,
qualitative
research
and
ideation
methodology
of
this
project.
We
will
also
go
into
more
detail
regarding
the
ideation
methodology
that
Harrison
Hayes
will
utilize
to
obtain
unique
insights
into
identifying
and
assessing
disruptive
areas
in
Advanced
Wound
Management
where
there
are
proven
unmet
needs,
including
identification
of
current
and
future
market
trends,
identification
of
technologies
and
products
to
be
in-­‐licensed
or
acquired,
and
make
recommendations
as
to
which
of
these
technologies
hold
the
greatest
promise
for
adoption.
To
complement
our
work
on
this
project,
Harrison
Hayes
will
rely
on
a
dynamic
network
of
KILs
(Key
Innovation
Leaders)
who
have
deep
domain
expertise
and
are
well
respected
in
their
specific
disciplines.
This
assures
that
our
research,
ideation
and
points
of
view
are
of
the
highest
value.
We
welcome
your
suggestions
and
comments
and
look
forward
to
a
great
working
relationship.
Sincerely,
Bill
Smith
Managing
Director
Harrison
Hayes,
LLC
Charlotte,
NC

3.
2
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
INTRODUCTION
Modern
wound
care
is
a
complex
process
supported
worldwide
by
obtuse
and
heterogeneous
funding
and
reimbursement
systems.
Wound
care
is
an
integral
part
of
all
areas
of
healthcare
and
all
types
of
practice,
and
the
patient
population
encompasses
the
spectrum
from
infants
to
the
elderly.
Wound
care
may
involve
acute
wounds
(e.g.,
trauma
and
surgical
incisions)
or
chronic
wounds
(e.g.,
pressure
ulcers,
or
vascular
or
diabetic
ulcers).i
Currently,
chronic
wound
and
ulcer
management
remains
one
of
the
most
costly
healthcare
challenges.
ii
In
the
US
alone,
complex
wounds
affect
more
patients
than
heart
attack
and
stroke
combined,
involving
5-­‐7
million
patients
and
over
$20
billion
in
healthcare
expenditures.
These
complex
wounds
result
in
approximately
150,000
amputations
a
year,
with
about
80,000
of
these
attributable
to
diabetes
and
peripheral
arterial
disease.iii
It
is
estimated
that,
globally,
biofilm
infections
alone
are
over
14
million,
accounting
for
more
than
350,000
deaths.iv
UK
NHS
Annual
spending
on
different
types
of
wounds.
From:
Tissue
viability
in
tomorrow’s
NHS.
R
White.
Journal
of
Wound
Care
17(3):97-­‐99.
Figure
3,
p.99.
March
2008.

4.
3
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
The
fundamental
paradigm
of
moist
wound
healing,
a
passive
approach
utilizing
dressings
and
technology
to
create
the
appropriate
conditions
for
healing
and
then
letting
the
wound
heal
itself,
has
not
shifted
significantly
since
its
inception
more
than
40
years
ago.v
The
longevity
of
this
paradigm
is
in
part
because,
in
most
cases,
this
model
is
successful.
However,
this
success
does
not
extend
to
the
most
challenging
complex
wounds,
such
as
diabetic
foot
ulcers
and
those
on
limbs
with
critical
limb
ischemia.
Notwithstanding
the
widespread
incidence
and
complex
nature
of
wounds
and
wound
care,
and
the
development
of
national,
regional,
and
international
guidelines,
relatively
few
patients
receive
state-­‐of-­‐the-­‐art
or
optimal
wound
care,
even
in
developed
countries.1
However
there
have
been
recent
indications
that
this
paradigm
is
beginning
to
shift
as
new
molecular
and
genetic
information
regarding
wound
healing
and
scar
development,vi,vii
and
microbiologic
information
regarding
biofilm
production
and
delayed
healing,
become
available.4
Wounds
from
surgery
and
trauma
are
by
far
the
most
common
types
of
wounds
and,
with
millions
of
surgical
procedures
performed
annually
worldwide,
the
market
for
wound
care
products
and
technologies
for
surgical
wounds
alone
is
significant.
Other
major
drivers
for
the
wound
care
industry
are
aging
of
the
population
and
advances
in
biotechnology
are
major
drivers
for
the
wound
care
industry.
As
the
population
ages
there
will
continue
to
be
increased
demand
for
surgical
interventions,
and
diabetic
ulcers
are
expected
to
continue
to
form
one
of
the
largest
sectors
of
this
market.
As
healthcare
lumbers
slowly
towards
personalized
medicine,
there
is
also
an
increasing
emphasis
being
made
on
personalization
of
wound
care,
a
major
shift
from
previous
generic
treatment
methods.
Increasingly,
physicians
are
directly
administering
Advanced
Wound
Care
Management
products
for
the
treatment
of
both
chronic
and
acute
wounds,
leading
to
greater
success
in
terms
of
wound
healing.
These
factors,
combined
with
a
drive
towards
home
healthcare
in
an
effort
to
gain
cost
efficiencies
while
improving
patient
outcomes,
acceptance
and
reimbursement
from
third-­‐party
payers,
increasing
professional
expertise
in
administering
advanced
wound
management
products,
improved
cost
effectiveness,
and
technological
advances
in
the
treatment
of
wounds,
are
all
expected
to
drive
the
market
over
the
next
five
years
and
beyond.viii

5.
4
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
From:
Worldwide
Wound
Management,
2009:
Established
and
Emerging
Products,
Technologies
and
Markets
in
the
U.S.,
Europe,
Japan
and
Rest
of
World.
MedMarket
Diligence.
September
2009.
The
U.S.
wound
management
market
was
valued
at
just
under
$5
billion
in
2009,
while
the
global
market
was
valued
at
over
$20
billion.ix
The
global
demand
for
wound
management
is
expected
to
increase
4.6%
per
year
through
2013
to
approximately
$28.7
billion.x
The
market
includes
therapeutic
support
surfaces,
static
and
dynamic
compression
therapy,
moist,
advanced,
and
interactive
wound
dressings,
wound
closure
devices,
hemostats,
tissue
sealants,
and
anti-­‐
adhesion.
The
internal
tissue
management
sector
comprised
40.8%
of
the
overall
market
in
the
US
in
2009,
with
expected
growth
in
this
sector
to
49.2%
by
2016
as
the
divide
between
external
and
internal
healing
diminishes.
This
change
is
attributable
to
the
movement
of
companies
traditionally
involved
in
durable
medical
equipment
and
medical
disposables
to
the
biologic
surgical
markets.xi

6.
5
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Demand
in
developing
countries
is
expected
to
expand
at
a
faster
rate
than
in
developed
countries,
although
approximately
75%
of
the
total
increase
in
the
wound
management
market
will
be
in
developed
countries
due
to
advanced
medical
delivery
systems
and
widespread
insurance
coverage
of
residents
for
primary
care
procedures.10
Wound
closures
will
remain
the
largest
segment
of
the
wound
management
market,
with
world
demand
expanding
3.5
percent
annually
to
$11.1
billion
in
2013,
although
advances
in
minimally
invasive
technologies
are
expected
to
inhibit
demand
beyond
this
level.
10,xii
Global
demand
for
wound
dressings
is
expected
to
increase
5.4
percent
annually
through
2013
reflecting
the
broad
indications
of
this
sector.
In
addition,
infection
control
standards,
which
promote
more
frequent
changes
of
wound
dressings,
in
combination
with
increased
utilization
of
biological
and
synthetic
wound
dressing
materials,
support
favorable
global
projections
for
wound
dressings.10
Advanced
Wound
Care
Management
in
the
form
of
emerging
wound
care
products
and
technologies
are
well-­‐positioned
to
capitalize
on
growth,
with
bioengineered
growth
factors
and
negative
pressure
devices
showing
the
fastest
gains
in
demand.10
Advanced
Wound
Care
Management
technologies
mimic
the
body’s
natural
physiology
and/or
regenerative
pathways
and
include
tissue-­‐engineered
skin
substitutes,
synthetic
and
harvested
regeneration
matrices,
autologous
grafts
and
biologically
active
cellular
therapies.xiii
These
technologies
first
emerged
in
1999
as
treatment
for
refractory
wounds,
and
today
there
are
a
number
of
products
currently
available,
with
others
in
pre-­‐clinical
or
clinical
development.
Recent
developments
include
changes
in
synthetic
dressing
materials
(e.g.,
hydrocolloid,
hydrofibre,
hydrogel,
alginate,
foam,
and
film);
Negative
Pressure
Wound
Therapy
(NPWT);
Antimicrobial
Wound
Dressings
(e.g.,
silver-­‐based
dressings);
and
Advanced
Therapies
(tissue
engineering
such
as
xenogeneic
tissue
scaffold,
bilayered
human
dermal
substitutes,
and
use
of
embryonic
stem
cells;
bio-­‐interactive
dressings;
collagen-­‐based
dressings;
and
hyaluronic
acid
and
growth
factors).xiv
In
addition,
surgical
techniques
such
as
endoscopic
subfascial
ligation
of
venous
perforators,
endovascular
arterial
repair
techniques,
have
become
important
in
surgical
and
trauma
wounds.xv
The
Bioengineered
and
Advanced
Wound
Care
Management
market
is
experiencing
continued
growth,
as
aging
of
the
population
in
developed
countries
leads
to
increasing
numbers
of
chronic
wounds
due
to
conditions
such
as
diabetes
which
are
forecast
to
grow
worldwide
during
the
next
fifteen
years.2
Advanced
Wound
Care
Management
technologies
and
therapies
currently
in
research/pre-­‐

7.
6
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
market/early
market
stage
include:
ultrasound
wound
cleaning,
activated
collagen,
manuka
honey,
noncontact
normothermic
wound
therapy,
tissue-­‐engineered
skin
substitutes
and
growth
factors.14
French
researchers
have
demonstrated
a
method
of
using
human
embryonic
stem
cells
to
create
new
skin
that
could
help
victims
of
serious
burns
by
having
readily
available
temporary
skin
with
a
low
level
of
rejection.xvi
Other
recent
studies
indicating
the
ability
of
these
technologies
to
facilitate
healing
in
otherwise
non-­‐healing
wounds
and
to
improve
patient
outcomes
places
them
on
a
competitive
field
in
terms
of
total
treatment
costs
despite
their
increased
individual
costs.
It
is
expected
that
the
number
of
indications
for,
and
third
party
payer
acceptance
of,
these
next-­‐generation
Advanced
Wound
Care
Management
technologies
will
drive
significant
growth
through
2015.2
In
the
Advanced
Wound
Care
Management
market
segment,
tissue-­‐engineering
products
have
a
very
small
market
share
with
$71.8
million
in
revenues
in
2008,
a
growth
rate
of
11.6%,
and
a
market
share
of
20.6%
of
overall
revenues.
Bio-­‐interactive
dressings
generated
the
highest
revenues
in
2008,
with
79.4%
share
of
overall
revenues.
The
tissue
engineering
segment
accounted
for
20.6
per
cent
of
the
overall
revenues.
Another
significant
area
for
expected
future
growth
within
the
Bioengineered
and
Advanced
Wound
Care
Management
market
is
the
development
of
biomarkers
for
healing,
for
differentiation
between
causes
of
non-­‐healing,
for
determination
of
biofilm
or
differentiation
between
planktonic
and
biofilm
phentoype
bacteria,
and
for
determination
of
susceptibility
of
wound
to
biomechanical
stimulation
of
healing
from
technologies
like
NPWT.
NPWT
is
also
expected
to
show
continued
growth
as
the
home
healthcare
equipment
market
continues
to
develop.8
The
global
NPWT
market,
with
2009
estimates
at
$640
million,
is
expected
to
show
growth
of
8.2%
annually
over
the
next
seven
years,
reaching
$1.1
billion
by
2016.
Drivers
for
this
growth
will
primarily
be
an
increasing
incidence
of
chronic
wounds,
diabetes,
and
an
aging
population.
Although
the
US
remains
the
largest
NPWT
market
valued
at
$380.6m
in
2009,
it
is
forecast
to
grow
by
7.7%
annually
for
the
next
seven
years
to
reach
$594.6m
in
2016.xvii
However,
most
of
the
demand
through
2016
will
be
originating
from
EU
economies,
creating
a
shift
in
the
center
of
global
NPWT
market
activity.
Italy,
France
and
Germany
are
expected
to
show
faster
NPWT
market
growth
than
other
market
sectors,
with
an
expectation
to
contribute
21%
by
2016,
driven
by
an
increasingly
diabetic
population
and
improvements
in
diabetes
and
wound
management.8,17

8.
7
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Europe
currently
appears
to
be
the
global
leader
in
integrating
advanced
wound
management
therapies
into
the
traditional
therapy
market.14
However
the
lack
of
standards
and
the
lack
of
common
organizations
across
EU
member
states
have
hindered
market
development,
leading
to
the
development
of
EU-­‐wide
organizations
such
as
the
Advanced
Wound
Care
(AWCS)
of
Eucomed
(European
Medical
Technology
Industry
Association).
In
addition,
the
move
toward
home
health
care
acts
as
a
market
restraint
until
the
healthcare
systems
better
fund
reimbursement
for
these
treatments.
Conversely,
as
EU
healthcare
systems
continue
a
paradigm
shift
from
traditional
to
high-­‐tech
treatment
modalities,
the
cost-­‐effectiveness
of
Advanced
Wound
Care
Management
therapies
and
technologies,
including
their
ability
to
be
used
as
part
of
home
treatments,
will
increase
in
importance
as
a
market
driver.
Consolidation
of
the
market
has
increased
the
ability
of
companies
to
fund
research
and
development,
as
well
as
overcome
the
regulatory
hurdles
of
each
of
the
EU
members,
allowing
for
more
rapid
introduction
of
new
therapies.
The
UK,
having
wider
acceptance
of
Advanced
Wound
Care
Management
technologies
and
therapies
by
the
medical
community,
and
reimbursement
of
all
phases
of
treatment,
has
the
highest
revenue
share
of
any
EU
market
(approximately
28.2%),
closely
followed
by
Germany
at
27.8%.14
Market
penetration
in
the
rest
of
the
EU,
where
market
share
currently
ranges
from
17.8%
in
France
to
about
5-­‐8%
in
the
rest
of
the
EU,
is
expected
to
increase
by
2015.14
The
EU
market
is
currently
more
favorable
towards
equipment-­‐based
and
other
advanced
therapy
modalities
than
towards
traditional
advanced
moist
dressings
for
chronic
wound
healing.14

9.
8
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
REFERENCES
i
Eucomed
Wound
Care
Policy
Paper.
September
23,
2009.
ii
Bioengineered
Wound
Care.
Greystone
Associates,
Aug
2009.
iii
Researchers
Develop
Device
To
Predict
Diabetic
Wound
Healing.
Medical
News
Today.
May
25,
2010.
http://www.medicalnewstoday.com/articles/189788.php.
iv
Chronic
wounds
and
the
medical
biofilm
paradigm.
R.D.
Wolcott,
D.D.
Rhoads,
M.E.
Bennett,
B.M.
Wolcott,
L.
Gogokhia,
J.W.
Costerton,
S.E.
Dowd.
Journal
Of
Wound
Care.
19(2):45-­‐53.
February
2010.
v
A
new
vision
for
wound
healing.
Tom
Pollard,
Ed.
Journal
of
Wound
Care.
17(4):141
April
2008.
vi
Lack
of
p21
expression
links
cell
cycle
control
and
appendage
regeneration
in
mice.
K
Bedelbaevaa,
A
Snydera,
D
Gourevitcha,
L
Clarka,
X-­‐M
Zhanga,
J
Leferovicha,
JM
Cheverudb,
P
Lieberman,
E
Heber-­‐Katz.
PNAS
107(13):5845-­‐5850.
March
30,
2010.
vii
Epithelial
to
Mesenchymal
Transition
in
Human
Skin
Wound
Healing
Is
Induced
by
Tumor
Necrosis
Factor-­‐
through
Bone
Morphogenic
Protein-­‐2.
C
Yan,
WA
Grimm,
WL
Garner,
L
Qin,
T
Travis,
N
Tan
and
Y-­‐P
Han.
Am
J
Pathol.
176(5):2247-­‐58.
May
2010.
viii
The
Future
of
the
US
Advanced
Wound
Management
Market
to
2012.
Aarkstore
Enterprise.
Mar
20,
2009.
ix
U.S.
Market
for
Wound
and
Tissue
Management
2010.
iData
Research
Inc.
December
2009.
World
Wound
Management
Products
(Industry
forecasts
for
2013
&
2018).
The
Freedonia
Group.
October
2010.
x
World
Wound
Management
Products
(Industry
forecasts
for
2013
&
2018).
The
Freedonia
Group.
October
2010.
xi
U.S.
Market
for
Wound
and
Tissue
Management
2010.
iData
Research
Inc.
December
2009.
xii
Western
European
Wound
Closure
Market.
Frost
&
Sullivan.
May
20,
2009.
xiii
Bioengineered
Wound
Care.
Greystone
Associates,
Aug
2009.
xiv
Western
European
Advanced
Wound
Management
Market.
Frost
&
Sullivan.
January
2,
2009.
xv
Wound
Care
Markets,
4th.
Edition,
Vol.
III:
Surgical
and
Trauma
Wounds
Apr
2009
Kalorama
Information.
xvi
Stem
cells
could
create
new
skin
to
help
burns
victims.
BBC
News.
November
20,
2009.
http://news.bbc.co.uk/2/hi/8368976.stm
xvii
Negative
Pressure
Wound
Therapy
(NPWT)
Pipeline
Technology
and
Market
Forecasts
to
2016.
GlobalData.
December
2009.

10.
9
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
SCOPE
It
is
our
understanding
that
CLIENT
X
would
like
Harrison
Hayes
to
investigate
the
unmet
needs
and
new
product
opportunities
within
mainstream
Advanced
Wound
Care
Management,
with
a
particular
but
not
exclusive
focus
on
Europe
for
adjacencies
that
leverage
CLIENT
X’s
current
competencies
in
Advanced
Wound
Care
Management
over
the
Near-­‐
to
Mid-­‐Term.
Harrison
Hayes
will
provide
a
thorough
review
of
the
future
of
the
European
and
global
Advanced
Wound
Care
Management
space,
with
identification
and
assessment
of
how
best
to
leverage
adjacencies
of
core
competencies
to
take
advantage
of
changing
technologies
and
therapies
within
the
Advanced
Wound
Care
Management
space
and
its
adjacencies.
OBJECTIVES
• Identification
and
review
of
unmet
needs
and
new
product
opportunities
particularly,
but
not
exclusively,
in
Europe
that
are
within
mainstream
Advanced
Wound
Management
and
that
would
create
value
generation
by
looking
out
three
to
five
years
(Mid-­‐
Term).
• Identification
of
Advanced
Wound
Care
Management
emerging
technologies
and
therapies,
and
companies
to
be
in-­‐licensed
or
acquired,
with
a
focus
on
Europe,
that
will
create
value
generation
within
three
to
five
years
(Mid-­‐Term).
• Identification
of
strategies
to
facilitate
and
increase
awareness
of
the
potential
return
on
investment
of
Advanced
Wound
Care
Management
emerging
technologies
and
opportunities
both
in
the
future
and
when
engaged
with
specific
opportunities
over
the
Mid-­‐Term,
with
a
particular
focus
on
Europe.
• Identification
of
current
and
future
trends
in
Advanced
Wound
Care
Management
adjacent
business
units
particularly,
but
not
exclusively,
in
Europe.

11.
10
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
METHODOLOGY
Harrison
Hayes
proposes
to
begin
the
project
by
meeting
with
CLIENT
X’s
project
team
to
conduct
due
diligence
and
review
currently
available
information.
The
purpose
of
this
meeting
is
to
verify
the
scope
of
the
assignment,
answer
questions,
and
review
the
timeline.
Harrison
Hayes
actively
engages
our
clients
in
collaborative,
interactive
dialogue
throughout
the
project.
We
suggest
weekly
meetings
to
review
and
assess
the
direction
and
progress
of
the
project.
METHODOLOGY
KOLs
The
project
will
begin
with
a
customized
Key
Opinion
Leader
Primary
Qualitative
Research
Module
designed
specifically
for
CLIENT
X.
Key
Opinion
Leaders
(“KOLs”)
are
recognized
experts
in
the
Advanced
Wound
Care
Management
industry.
We
will
look
to
these
KOLs
to
provide
valuable
insight
into
the
best
mechanisms
for
leveraging
of
adjacencies
to
core
competencies
in
Advanced
Wound
Care
Management
particularly,
but
not
exclusively,
in
Europe.
The
KOL
questionnaire
will
be
developed
through
a
collaborative
effort
with
CLIENT
X
in
order
to
ensure
that
the
focus
of
this
project
is
being
properly
addressed.
The
questionnaire
is
to
be
used
as
a
platform
for
exploration
and
discussion.
All
interviews
will
be
conducted
directly
by
Harrison
Hayes’s
Principals
and
Research
Team
who
have
the
autonomy
to
probe
deeper
and
maneuver
through
unique
issues
that
arise
during
discussion
with
the
KOLs
–
what
we
refer
to
as
improvisational
interviewing.
Our
Research
Team
is
able
to
select
the
most
appropriate
questions
to
ask
each
KOL
due
to
our
extensive
knowledge
and
involvement
with
the
project’s
goals.
These
interviews
are
conducted
individually,
which
allows
us
to
focus
directly
on
the
expertise
that
each
KOL
possesses.
Improvisational
interviewing
yields
valuable
qualitative
interview
data
unlike
structured
interview
surveys.
Instead
of
merely
moving
from
question
to
question,
our
Research
Team
is
able
to
adapt
based
on
KOLs’
response
to
questions,
thus
obtaining
additional
insight.

12.
11
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
METHODOLOGY
Secondary
Research
To
complement
our
Primary
Qualitative
Key
Opinion
Leader
research
we
will
concurrently
perform
secondary
research
from
syndicated,
internal,
and
public
sources.
We
believe
secondary
research
will
provide
us
with
useful
data
regarding
current
and
future
trends
in
advanced
wound
care
technology
particularly,
but
not
exclusively,
in
Europe.
We
will
look
to
uncover
macro
trends
impacting
CLIENT
X’s
core
competencies
and
future
opportunities,
with
a
focus
on
Mid-­‐
Term
opportunities
and
trends.
Our
Secondary
Research
Methodology
and
its
role
in
the
project’s
outcome
are
discussed
in
further
detail
below.
Harrison
Hayes
believes
that
through
the
effective
marrying
of
primary
KOL
insight
and
secondary
research
–
along
with
our
partnership
with
the
CLIENT
X
project
team
–
we
can
obtain
uncommon
insight
into
the
potential
to
determine
how
best
to
leverage
core
competencies
in
Advanced
Wound
Care
Management
particularly,
but
not
exclusively,
in
Europe.
Our
research
module
begins
by
concurrently
identifying
and
recruiting
a
customized
panel
of
Key
Opinion
Leaders
(Tables
1
and
2)
and
developing
a
project
specific
Key
Opinion
Leader
questionnaire
(Table
3).
Please
note
that
the
questions
in
Table
3
are
examples
and
not
all-­‐inclusive
of
what
we
will
ultimately
ask.
METHODOLOGY
KOLs
Table
1:
Examples
of
Key
Opinion
Leaders
(Note:
Additional
KOLs
will
emerge
from
Selected
Representative
Areas)
• Pharmacologists,
Immunologists,
Tissue
Engineers,
Nanotechnology
and
Nanomedicine
Specialists,
Biomaterials
Specialists,
Proteomic
and
Genomic
Specialists,
and
Medical
Device
Specialists
with
a
European
and
global
focus
• Board
of
Directors
for
Advanced
Wound
Care
Device
Manufacturers
with
a
European
and
global
focus
• Physicians
from
Representative
Institutions
Published
in
Advanced
Wound
Care
Technologies
and
Therapies
with
a
European
and
global
focus
• Academic
Thought
Leaders
Involved/Published
in
Advanced
Wound
Care
Technologies
and
Therapies
with
a
European
and
global
focus

13.
12
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
• Academic
Thought
Leaders
Involved/Published
in
Pharmacology,
Immunology,
Dermatology,
Surgery,
Orthopedics,
Plastic
Surgery,
Nanotechnology,
Nanomedicine,
Proteomics,
Genomics,
Tissue
Engineering,
Biomaterials,
and
Medical
Devices
Relevant
to
Advanced
Wound
Care
with
a
European
and
global
focus
• Strategic
Leaders
in
Advanced
Wound
Care
Technologies
and
Therapies
with
a
European
and
global
focus
• Decision
Makers
for
National
Advanced
Wound
Care
Technologies
and
Therapies
Regulatory
and
Reimbursement
Policy
with
a
European
and
global
focus
METHODOLOGY
Potential
KOLs
Table
2:
Examples
of
Potential
Key
Opinion
Leaders
(Note:
Additional
KOLs
will
emerge
from
Selected
Representative
Areas)
Name
Title
/
Expertise
Organization
/
Location
Zena
Moore,
MSc,
FFNMRCSI,
PG
Dip,
Dip
Management,
RGN
President,
Dept.
of
Nursing
and
Midwifery,
European
Wound
Management
Association.
Lecturer
in
Wound
Healing
&
Tissue
Repair
and
Research
Methodologies,
Royal
College
of
Surgeons
in
Ireland
Dept.
of
Nursing
and
Midwifery
Royal
College
of
Surgeons,
Ireland
Dublin,
Ireland
Marco
Romanelli,
MD,
PhD
Extensive
clinical
experience
managing
leg
ulceration
patients;
responsible
for
Critical
Wounds
Clinic
at
University
Hospital
of
Pisa;
coordinated
European
Pressure
Ulcers
Prevalence
Project;
Immediate
Past
President,
European
Wound
Management
Association.
Dept.
of
Dermatology
University
of
Pisa
Pisa,
Italy
Patricia
Price,
Ph.D.,
A.F.B.Ps.S.,
Chartered
Health
Psychologist
/
Director
of
the
Wound
Healing
Research
Unit
in
Cardiff
at
University
of
Wales
College
of
Medicine;
Honorary
Secretary,
European
Wound
Management
Association
Director
of
the
Wound
Healing
Research
Unit
Cardiff
University
of
Wales
College
of
Medicine
Cardiff
University
Cardiff,
UK
Sue
Bale,
Dr,
FRCN,
PhD,
BA,
RGN,
NDN,
RHV,
PG
Dip,
Dip
Nursing
Wound
healing
research
expert
spanning
21
years;
110
publications
in
peer-­‐reviewed
journals;
14
books
&
chapters;
62
international
conference
papers;
28
posters
at
international
conferences,
and
12
videos
&
CDs.
Recorder,
European
Wound
Management
Association
Gwent
Healthcare
NHS
Trust
Torfaen,
Wales

14.
13
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Peter
Carmeliet
Research
in
Role
of
VEGF
in
angiogenesis
in
health
and
disease;
Therapeutic
antiangiogenesis
with
anti-­‐PlGF;
Therapeutic
revascularization
of
ischemic
tissues;
Therapeutic
hibernation
of
ischemic
tissues;
Endothelial
normalization
to
prevent
metastasis
&
promote
therapeutic
revascularization
of
ischemic
tissues;
VEGF
therapy
for
neurodegeneration;
Oxygen
Sensors
at
the
crossroads
of
metabolism
&
angiogenesis
Vesalius
Research
Centrum
O&N
I
Herestraat
49
-­‐
bus
00912
B-­‐3000
Leuven
Bernard
Coulomb,
PhD
Wound
healing,
dermal
skin
substitute,
research
scientist;
co-­‐founder
ScarCell
Therapeutics;
European
Tissue
Repair
Society
Board.
INSERM
U532
Institut
de
Recherche
sur
la
Peau
Pavillon
Bazin,
Hôpital
Saint-­‐Louis,
1
avenue
Claude
Vellefaux
75475
Paris
cedex
10,
France
Finn
Gottrup,
MD,
DM
Sci
Leading
global
specialist
on
wound
healing;
more
than
15
years’
experience
with
treatment
of
chronic
wounds;
key
figure
in
establishment
of
the
first
two
interdisciplinary
wound
healing
centers
in
Denmark:
University
Hospital
of
Odense
and
Bispebjerg
Hospital;
Prof
of
Surgery.
University
of
Southern
Denmark,
University
Center
of
Wound
Healing,
Department
of
Plastic
and
Reconstructive
Surgery,
Odense
University
Hospital,
Denmark
Martin
Koschnik
Since
2006
represents
German
Wound
Healing
Society
(DGfW)
in
the
EWMA;.
DGfW
made
enormous
efforts
to
develop
and
promote
several
evidence-­‐based
wound
healing
projects
(evidence-­‐based
education
curriculum
for
nurses
and
doctors
&
an
evidenced-­‐based
guideline
on
topical
treatment
of
chronic
wounds
in
patients
with
severe
risks).
Hospital/Clinic
Instituto
Português
de
Oncologia
de
Lisboa
Francisco
Gentil,
EPE
Rua
Professor
Lima
Basto
Lisbon
1099-­‐023
PORTUGAL
Jean-­‐Jacques
Lataillade
Stem
Cells
and
Cell
Therapy;
CTSA
representative
to
STEM-­‐Pole;
European
Tissue
Repair
Society
Board
Service
de
Santé
des
Armées
(SSA)
/
Thérapie
cellulaire
des
brûlures
graves
-­‐
Hôpital
Militaire
Percy
Clamart
Unité
de
recherche
:
Hôpital
d'instruction
des
armées
Percy
101,
avenue
Henri
Barbusse
BP
406
92141
Clamart
Cedex
Liliane
Michalik
PhD
in
microtubule-­‐associated
proteins
in
the
group
of
Jean-­‐François
Launay,
INSERM;
post-­‐
doctoral
training
in
elucidating
the
roles
of
the
nuclear
hormone
receptors
PPARs
in
skin
homeostasis
and
repair;
research
in
skin
repair,
UV
induced
skin
cancer,
angiogenesis,
peroxisome
proliferator-­‐activated
receptors.
UNIL
Genopode
Building
CH
-­‐
1015
Lausanne,
Switzerland
Filip
Stillaert
Assisting
academic
staff;
flap-­‐graft
viability;
tissue
engineering.
Department
of
Plastic
Surgery,
Gent
University
Hospital,
De
Pintelaan
185,
B-­‐9000
Gent,
Belgium.
Miikka
Vikkula,
MD,
PhD
Professor
of
Human
Genetics;
genetics
of
vascular
anomalies;
mechanisms
of
altered
angiogenesis.
Laboratory
of
Human
Molecular
Genetics
de
Duve
Institute
Université
catholique
de
Louvain
Avenue
Hippocrate
74,
BP
75.39,
B-­‐1200
Brussels,
Belgium.

15.
14
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Sabine
Werner,
PhD
Research
interests
in
molecular
&
cellular
mechanisms
of
cutaneous
wound
repair
&
parallels
to
cancer;
mechanisms
underlying
UV-­‐
induced
skin
damage;
pathogenesis
of
inflammatory
skin
disease.
HPM,
D
42
Schafmattstrasse
18
8093
Zurich
SWITZERLAND
Keith
Harding
MB
MRCGP
FRCS
Trained
in
general
surgery
and
in
family
medicine
with
longstanding
interest
in
wound
healing;
Clinical
Director
of
the
Wound
Healing
Research
Unit;
Head
of
the
Department
of
Surgery
and
Professor
of
Rehabilitation
Medicine
(Wound
Healing);
specializes
in
treating
wound
healing
problems;
has
authored
over
250
publications
and
a
number
of
books
on
wound
healing;
First
President
of
European
Pressure
Ulcer
Advisory
Panel,
First
Recorder
of
European
Wound
Management
Association
and
current
President
of
the
European
Tissue
Repair
Society.
Professor
of
Rehabilitation
Medicine
(Wound
Healing)/
Director
Wound
Healing
Research
Unit
Cardiff
Medicentre
Heath
Park
Cardiff
CF14
4UJ
Gary
Sibbald,
MD,
FRCPC,
ABIM,
DABD,
Med
Director
of
the
Wound
Healing
Clinic
at
the
Women's
College
Hospital
of
Toronto;
President
Elect
of
World
Union
of
Wound
Healing
Societies
Women's
College
Research
Institute
790
Bay
Street;
7th
floor
Toronto,
ON
M5G
1N8
Canada
Sabine
Eming
MD,
PhD
Research
aimed
at
understanding
of
repair
response
at
molecular
level;
identification
of
genes,
signals
&
mechanisms
that
determine
cell
function
during
skin
repair;
manipulation
of
healing
response
to
develop
regeneration
&
novel
strategies
for
drug
interventions
in
pathological
healing
conditions
in
diabetes
mellitus,
vascular
diseases
or
aging;
interrelation
between
tissue
repair,
mechanisms
of
cancer
development
&
inflammatory
skin
diseases.
Department
of
Dermatology
Joseph-­‐Stelzmann
Str.
9
50931
Cologne,
Germany
Hilde
Beele,
MD,
PhD
Board
Member
&
Treasurer
European
Society
for
Tissue
Repair;
Head
of
the
Tissue
Bank;
Dermatologist;
Medical
Director
Ghent
Univ.
Hospital;
research
interests
in
wound
bed
preparation
&
healing,
graft
rejection
&
survival.
Ghent
University
Hospital
Tissue
Bank
&
Dep’t
of
Dermatology
Ghent,
Belgium
Boris
Hinz,
PhD
Chair
of
Cell
Contractility
Group;
pathobiology
and
biophysics
of
fibroblasts;
fibrocontractive
diseases,
wound
healing,
tissue
remodeling,
repair
&
regeneration;
cell
biology,
bioengineering,
cell
biophysics
&
biomechanics,
experimental
pathology,
experimental
dermatology,
theoretical
biology,
biomedical
imaging;
cell
contraction
&
motility;
actin
isoforms
&
actin-­‐associated
proteins;
cell-­‐cell
and
cell-­‐matrix
contacts,
mechano-­‐transduction
Laboratory
of
Tissue
Repair
and
Regeneration,
Matrix
Dynamics
Group,
Faculty
of
Dentistry,
Fitzgerald
Building,
University
of
Toronto,
150
College
Street,
Toronto,
ON
M5S
3E2,
Canada
Gerrolt
Jukema,
MD
Trauma
Surgeon
Working
to
bring
the
EWMA
further
in
the
field
research
and
evidence
based
medicine
&
to
set
an
evidence
based
standard
in
wound
care.
VU
University
Medical
Centre
Head
of
the
Department
of
Trauma
Surgery
Amsterdam,
The
Netherlands

16.
15
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Dimitris
Kletsas,
PhD
Research
interests
in
mechanisms
of
cellular
senescence
&
its
role
in
age-­‐related
disorders
(cancer,
intervertebral
disc
degeneration,
chronic
wounds);
growth
factor-­‐
and
stress-­‐
regulated
signaling
pathways;
extracellular
matrix;
bioactive
compounds
from
natural
products;
cell
replacement
therapy.
Institute
of
Biology,
N.C.S.R.
"Demokritos"
153
10
Athens,
Greece
David
Leaper,
MD,
ChM,
FRCS,
FACS
Research
interests
in
surgical
infection,
sepsis,
wound
healing;
editor
and
referee
for
several
journals;
past
president,
Surgical
Infection
Society
of
Europe
&
European
Wound
Mgmt
Association;
past
Hunterian
Professor
&
Zachary
Cope
lecturer
at
Royal
Coll
Surg;
published
over
10
books,
50
chapters
&
250
research
&
review
papers;
invited
speaker
to
many
societies;
chaired
&
organized
national/international
committees;
speaker/medical
advisor
for
companies
in
Pharmaceutical
Industry.
Emeritus
Professor
of
Surgery,
University
of
Newcastle
upon
Tyne
and
Visiting
Professor,
Department
of
Wound
Healing
Cardiff
University
Wales,
UK
Rita
Gaspar
Videira
In
clinical
practice
since
1991
at
S.
João
Universitary
Hospital,
in
Porto;
invited
to
private
medicine
for
years;
has
developed
a
particular
interest
in
wound
management.
Hospital
S.
João,
E.P.E.
Porto,
Portugal
Jose
Verdu
Soriano
Ph.D.
Thesis:
Epidemiology,
prevention
and
treatment
of
pressure
ulcers
Master
in
Nursing
Sciences
(MScN).
University
of
Alicante,
2007
Departamento
de
Enfermería
Comunitaria
Campus
de
Sant
Vicent
del
Raspeig
Alicante,
Spain
Rytis
Rimdeika
Head,
Dep’t
of
Plastic
&
Reconstructive
Surgery,
Kaunas
Medical
University
Hospital;
Hospital
Director
for
Surgery
Department
of
Surgery
Kaunas
Medical
University
Hospital
Kaunas,
Lithuania
Sylvie
Meaume
Co-­‐founder,
French
Journal
of
Wound
Care
"Journal
des
Plaies
et
Cicatrisations".
1996;
Co-­‐
organizer
of
the
annual
French
National
Meeting
'"Conférence
des
Plaies
et
Cicatrisations"
(more
than
3500
participants);
Président
of
the
French
Society
of
Wound
Healing
2006-­‐2009
Geriatric
Ward
Charles
Foix
Hospital
(Assistance
Publique
de
Paris)
Paris,
France
Severin
Lauchli
Staff
physician,
Dermatological
Clinic,
University
Hospital,
Zürich;
Responsible
for
Dermatologic
Surgery
and
Wound
Care
Dermatological
Clinic
University
Hospital,
Zürich
Zürich,
Switzerland
Maarten
Lubbers
Inflammation;
wounds
(healing,
infection,
dressings,
tissue
engineering);
transplantation;
infection;
sepsis;
MOF;
antiseptics;
evidence;
health
economics;
guidelines.
Academisch
Medisch
Centrum
Amsterdam,
Netherlands
Martin
Koschnick
Basic
principles
of
wound
healing:
model
for
development
of
granulation
tissue
in
rodents;
receptor
status
in
wound
healing
by
FACS;
molecular
biology
in
wound
healing,
role
of
p53;
analysis
of
mechanism
of
hypopressure
bandage;
investigations
of
role
of
disinfectants
in
healing
National
Cancer
Institute
Lisbon,
Portugal

17.
16
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Marcus
Gurgen
Treatment
of
all
chronic
wounds;
Established
Wound
Healing
Unit
at
Sørlandet
Sykehus;
special
interest
in
diabetic
foot
ulcers;
published
articles
on
the
diabetic
foot;
research
in
fields
of
pH
in
chronic
wounds
and
growth
factor
treatment;
Lectures
on
chronic
wound
healing
for
institutions,
medical
societies
and
companies.
Sørlandet
Sykehus
HF
Flekkefjord,
Norway
Corrado
Durante
Chief
of
the
Vulnotherapy
Unit,
Emergency
Dept.
Army
Military
Hospital
of
Rome
Wound
Care
Unit
Army
Military
Hospital
Piazza
Celimontana
50
00184
Roma
ITALIA
Carol
Dealey
Senior
Research
Fellow,
University
Hospital
Birmingham
NHS
Foundation
Trust;
Research
Fellow,
School
of
Health
Sciences,
University
of
Birmingham/University
Hospital
Birmingham
NHS
Trust;
Research
Fellow,
University
Hospital
Birmingham
NHS
Trust;
Clinical
Nurse
Specialist
in
Tissue
Viability,
Community
Hospitals
Division,
Southern
Birmingham
Community
Health
NHS
Trust;
Clinical
Nurse
Specialist
in
Tissue
Viability,
Queen
Elizabeth
Hospital,
EWMA
Journal
Editor
University
Hospital
Birmingham
NHS
Foundation
Trust
Birmingham,
UK
Paulo
Alves
Member
of
Portuguese
Red
Cross;
volunteer
Nurse
since
1999;
Trustee
EPUAP
–
European
Pressure
Ulcer
Advisory
Panel,
since
2007;
Member
of
Scientific
Committee
of
EWMA
2008
Member
of
APTFeridas
–
Portuguese
Wound
Management
Association,
board
since
2008
Member
of
APNEP
–
Portuguese
Association
of
Nutrition,
since
2008
CHVNG
-­‐
Centro
Hospitalar
Vila
Nova
de
Gaia
Vila
Nova
de
Gaia,
Portugal
Robert
Strohal
Past
president
of
Austrian
Wound
Management
Association;
current
Vice-­‐president;
European
Commission-­‐funded
concerted
action
on
genetic
skin
diseases
(GENESKIN
incl.
epidermolysis
bullosa);
various
investigator
originated
studies
with
a
special
focus
on
new
options
for
the
clinical
management
of
MRSA,
infection
and
pain
in
acute
and
chronic
wounds;
8
national
and
international
scientific
awards.
Federal
University
Teaching
Hospital
of
Feldkirch
Department
of
Dermatology
Feldkirch,
Austria
Simon
Kay,
MD
Immediate
Past
President
of
BAPRAS;
Chairman,
BAPRAS'
Professional
Standards
Committee;
consultant
plastic
surgeon;
special
interest
in
hand
surgery,
microsurgery,
children’s
surgery
and
breast
surgery;
Professor
of
Hand
Surgery,
University
of
Leeds;
current
research
includes
joint
collaboration
on
nerve
repair
with
Umeä
University
in
Sweden
(Hon.
Visiting
Prof.
in
Plastic
and
Hand
Surgery).
Univeersity
of
Leeds
Leeds,
UK
Umea
University
Plastic
and
Hand
Surgery

18.
17
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Hiroshi
Nishikawa,
MD
Joined
BAPRAS
Council
in
2008
and
will
remain
on
the
Council
until
the
end
of
2010;
BAPRAS
representative
on
Intercollegiate
Board
in
Plastic
Surgery
from
2008
until
2013;
main
area
of
specialty
is
craniofacial
surgery.
The
Children's
Hospital
and
Priory
Hospital
Birmingham,
UK
Nicholas
Parkhouse
Special
interest
in
aesthetic/cosmetic
surgery
of
the
face,
breasts,
abdomen
and
trunk,
together
with
non-­‐surgical
injection
and
laser
treatment
for
specific
problems;
special
interest
in
the
treatment
of
scarring
disfigurement.
McIndoe
Surgical
Centre
London,
UK
Peter
Franks,
PhD
Past
President
of
the
European
Wound
Management
Association;
Professor
of
Health
Sciences.
Centre
for
Research
and
Implementation
of
Clinical
Practice,
Thames
Valley
University
London,
United
Kingdom
Pr.
Frank
Duteille,
MD
Head
of
the
Department
of
Plastic
Reconstructive
and
Esthetic
Surgery
University
Hospital
Nantes,
France
Dieter
Mayer,
MD
Vascular
Surgeon,
EBSQ-­‐VASC,
FMH;
Senior
Consultant,
Vascular
Surgery;
Head
of
Wound
Care
Zurich
University
Hospital
Zurich,
Switzerland
Thomas
Wild,
MD
Department
of
Surgery,
University
of
Vienna;
President
Elect
of
Austrian
Wound
Association
Department
of
Surgery
University
of
Vienna
Vienna,
Austria
Mona
Baharestani,
PhD,
ANP,
CWOCN,
CWS
Associate
Professor
&
Secretary
for
the
Advancement
of
Wound
Care,
Center
for
Nursing
Research,
East
Tennessee
State
University;
Faculty
Professor,
Oxford
University
Wound
Healing
Summer
School,
UK
Oxford
University
Wound
Healing
Summer
School,
UK
Professor
Dr.
Med.
Matthias
Augustin
Professor
for
Health
Economics
&
Quality
of
Life
Research
Group,
Department
of
Dermatology,
University
Clinics
of
Hamburg,
Germany
Department
of
Dermatology
University
Clinics
of
Hamburg
Hamburg,
Germany
Walter
Ingram,
MD
Director
of
Grady
Memorial
Hospital
Burn
Unit;
compiled
extensive
patient
database
used
as
fundamental
tool
in
outcomes
research;
clinical
specialties
include
chemical
&
electrical
burns,
surgical
critical
care,
skin
grafts,
&
herpes
donor
site
studies;
research
interests
include
patient
outcomes
post-­‐skin
replacement,
outcomes
of
diabetic
patients
with
burned
feet,
&
investigation
of
skin
graft
donor
sites
infected
with
herpes
virus.
Grady
Memorial
Hospital
Campus
Glenn
Memorial
Building
Room
304
69
Jesse
Hill
Jr.
Drive,
SE
Atlanta,
GA
30303
Jeremy
Tamir,
MD
Senior
Plastic
Surgeon;
Director
of
the
Wound
Care
Center
at
Sheba
Medical
Center
in
Israel;
founder
&
chairman
of
Israeli
Wound
Healing
Society;
research
on
advanced
technologies
in
wound
care;
Head
of
the
Wound
Care
and
Plastic
Surgery
Departments.
Sheba
Medical
Center
Israel
Wound
Care
and
Plastic
Surgery
Departments
at
Halstead
Hospital
in
Kansas,
USA.

19.
18
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Chandan
K.
Sen,
PhD
Department
of
Surgery
&
Molecular
&
Cellular
Biochemistry;
focuses
on
reactive
oxygen
species
&
anti-­‐oxidant
nutrients
with
emphasis
on
tissue
injury
and
repair;
Executive
Director
of
OSU
Comprehensive
Wound
Ctr.
The
Ohio
State
University
Comprehensive
Wound
Center.
Stephen
M.
Milner,
MD
Director
of
Surgery,
Johns
Hopkins
Wound
Center;
Director,
Johns
Hopkins
Burn
Center;
specialties
include
acute
burns,
burn
deformities,
facial
cancers,
necrotizing
fasciitis,
TEN
and
complex
injuries,
scars,
acute
&
reconstr.
burn
surgery,
surgical
management
of
complex
wounds,
facial
reconstruction.
The
Johns
Hopkins
Burn
Center
at
the
Johns
Hopkins
Bayview
Medical
Center.
Harriet
Hopf,
MD
Professor,
Department
of
Anesthesiology;
research
focuses
on
measuring
tissue
oxygen
&
improving
wound
healing
outcomes
by
increasing
oxygen
delivery.
University
of
Utah
Department
of
Anesthesiology
Room
3C444
30
N.
1900
East
Salt
Lake
City,
UT
84132
Lisa
Gould,
MD
Chief,
Plastic
Surgery;
Professor
of
Medicine
at
Univ.
of
South
Florida;
Secretary
of
the
Wound
Healing
Society
James
A.
Haley
Veterans'
Hospital
Department
of
Surgery
13000
Bruce
B.
Downs
Blvd.
Tampa,
FL
33612
Andrew
Baird,
PhD
Professor,
Department
of
Surgery,Division
of
Trauma,
Burns
and
Wounds
University
of
California
San
Diego
Department
of
Surgery
Division
of
Trauma,
Burns
and
Wounds
212
Dickenson
Street
Mail
Stop
8236
San
Diego,
CA
92103
Stephanie
Bernatchez,
PhD
Advanced
Research
Specialist
at
3M
3M
Skin
and
Wound
Care
Division
3M
Center
Bldg,
270-­‐3N-­‐03
St.
Paul,
MN
55144
Nicole
Gibran,
MD
Research
emphasizes
aberrant
healing
process
including
hypertrophic
scar
formation
and
chronic
non-­‐healing
wounds
seen
with
diabetes;
has
over
100
publications
in
wound
repair,
response
to
injury
and
burns;
Director
of
the
UW
Burn
Center
Harborview
Medical
Center
Department
of
Surgery
325
Ninth
Ave.
Box
359796
Seattle,
WA
98104
Robert
Kirsner,
MD,
PhD
Director
Univ.
of
Miami
Hospital
Wound
Center;
Chief,
Dermatology
Dep’t,
Univ.
of
Miami
Hospital;
Co-­‐directs
Symposium
for
Advanced
Wound
Care;
serves
on
planning
committee
for
several
meetings;
editorial
boards
for
dermatology
and
wound
care
journals;
board
member
of
Wound
Healing
Society;
past
president
Association
for
the
Advancement
of
Wound
Care;
chairs
Medical
Advisory
Board
for
National
Healing
Corp.
University
of
Miami
Department
of
Dermatology
1600
NW
10th
Avenue
RMSB
2023A
Miami,
FL
33136
Lillian
Nanney,
PhD
Investigates
cutaneous
growth
control
mechanisms
in
skin
in
wound
healing
settings
or
whether
in
benign
or
neoplastic
growth.
Vanderbilt
University
Medical
Center
Plastic
Surgery,
Research
Laboratories
S-­‐221
MCN,
1161
21st
Ave.
S.
Nashville,
TN
37232

20.
19
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Laura
Parnell,
MS,
CWS
Founded
Precision
Consulting;
specializes
in
wound
healing
&
burn
research;
designs
research
protocols,
develops
scientific
niche
products;
international
clientele
including
industry,
FDA,
&
research
investigators.
Precision
Consulting
Clinical
Research
6522
Harbor
Mist
Missouri
City,
TX
77459
Joyce
Stechmiller,
PhD,
ACNP-­‐BC,
FAAN
Chronic
wound
healing;
Chair
of
Adult
&
Elderly
Nursing
Department
(1998-­‐2002);
Director
of
Biobehavioral
Research
Center
(NINR
P-­‐20);
American
Society
of
Enteral
&
Parenteral
Nutrition
(Secretary,
Nursing
Section)
&
Wound
Healing
Society
Education
Cmte.
University
of
Florida
College
of
Nursing
Adult
and
Elderly
Nursing
HPNO
Box
100187
Gainesville,
FL
32610
Paul
Takahashi,
MD
Research
interests
involve
geriatrics
and
the
normal
process
of
aging;
wound
care.
Bruce
Cairns,
MD
Director,
NC
Jaycee
Burn
Center;
critical
care,
general
surgery,
trauma,
burns,
cellular
immunology,
shock,
electrical
injury,
wound
healing,
disaster
management,
telemedicine.
Division
of
NC
Jaycee
Burn
Center
CB
#7600
UNC
Department
of
Surgery
Chapel
Hill,
NC
27599
David
B.
Drake,
M.D.
Associate
Professor
of
Plastic
Surgery,
UVA;
Co-­‐
director
UVA
Hand
Fellowship;
Medical
Director,
DeCamp
Burn
and
Wound
Center.
Plastic
and
Reconstructive-­‐Uva
101
Hospital
Dr
#4621
Charlottesville,
VA
22908-­‐0001
Toshiharu
Ishii,
MD,
PhD
President,
Japanese
Society
for
Wound
Healing
Professor
and
Chairman,
Department
of
Pathology,
School
of
Medicine.
Toho
University
School
of
Medicine
Department
of
Pathology
5-­‐21-­‐16
Omori-­‐nishi
Otaku,
Tokyo
143-­‐8540,
Japan
Tal
Ellis
Vice
president,
Australian
Wound
Management
Association.
WOUNDHEAL
AUSTRALIA
PO
Box
3454
Norwood,
SA
5067,
Australia
Robert
Mullegger,
MD
President,
Austrian
Wound
Association
and
Scientific
Society
of
Dermatologists,
Executive
Board,
Dep’t
of
Dermatology
at
State
Hospital.
Austrian
Society
for
Dermatology
and
Venereologie,
Corvinusring
3-­‐5
A
2700
Wiener
Neustadt,
Austria
Thomas
Wild,
MD
President
Elect,
Austrian
Wound
Association.
Univ.
of
Salzburg,
Institute
of
Nursing
Sciences,
Paracelsus
Medical
Strubergasse
21,
A-­‐5020
Salzburg,
Austria
Frank
Duteille,
MD
Head
of
Department
of
Plastic
Reconstructive
and
Esthetic
Surgery,
University
Hospital.
University
Hospital
Nantes,
France
Dieter
Mayer,
MD
Vascular
Surgeon,
EBSQ-­‐VASC,
FMH;
Senior
Consultant
of
Vascular
Surgery
&
Head
of
Wound
Care.
University
Hospital
Zurich
Raemistrasse
100
CH-­‐8091
Zurich
Switzerland
Darrell
S.
Rigel,
MD,
MS
Clinical
Professor
of
Dermatology
New
York
University
School
of
Medicine
New
York,
New
York
Mark
Lebwohl,
MD
Professor
and
Chairman,
Department
of
Dermatology.
Mount
Sinai
School
of
Medicine
New
York,
New
York
Dee
Anna
Glaser,
MD
Professor
&
Vice
Chairman,
Department
of
Dermatology.
Saint
Louis
University
2325
Dougherty
Ferry
Road,
Suite
102
Department
of
Dermatology

21.
20
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Sheila
Fallon
Friedlander,
MD
Clinical
Professor
of
Pediatric
and
Medicine.
UCSD
Division
of
Pediatric
Dermatology
Rady
Children's
Hospital
and
Health
Center
8010
Frost
Street,
Suite
602
San
Diego,
CA
92123
Timothy
C.
Flynn,
MD
Clinical
Professor,
Department
of
Dermatology;
Medical
Director,
Cary
Skin
Ctr.
Cary
Skin
Center
200
Wellesley
Trade
Lane
Cary,
NC
27519
Boni
E.
Elewski,
M.D.
Vice-­‐Chair
for
Clinical
Affairs
University
of
Alabama
at
Birmingham
EFH
414
1530
3RD
AVE
S
BIRMINGHAM
AL
35294-­‐0009
Roger
I.
Ceilley,
MD
Assistant
Clinical
Professor
of
Dermatology
at
Department
of
Dermatology
Department
of
Dermatology
University
of
Iowa
Hospitals
and
Clinics
200
Hawkins
Drive
Iowa
City,
IA
52242
Roy
S.
Rogers,
III,
M.D.
Professor
of
Dermatology,
Mayo
Medical
School;
Consultant
in
Dermatology,
Mayo
Clinic;
Dean,
Mayo
School
of
Health-­‐Related
Sciences
Mayo
Medical
Clinic
200
1st
Ave
E
5B
Rochester,
MN,
55905
John
J.
Zone,
MD
Chairman
and
Professor
of
Dermatology.
University
Health
Care
Department
of
Dermatology
30
North
1900
East,
4A330
School
of
Med
SLC
UT
84132
June
K.
Robinson,
MD
Section
Chief
of
Dermatology
at
Dartmouth-­‐
Hitchcock
Medical
Center.
Norris
Cotton
Cancer
Center
One
Medical
Center
Drive
Lebanon,
NH
03756
Brett
Coldiron,
MD,
FACP
Clinical
Assistant
Professor,
University
of
Cincinnati
The
Skin
Cancer
Center.
The
Skin
Cancer
Center
Cincinnati,
OH
Elizabeth
Alvarez
Connelly,
MD
Assistant
Professor
of
Dermatology,
Department
of
Dermatology
&
Cutaneous
Surgery;
Assistant
Professor,
Department
of
Pediatrics,
Division
of
Pediatric
Dermatology.
University
of
Miami
Miller
School
of
Medicine
Joseph
L.
Jorizzo,
MD
Professor,
Former
and
Founding
Chair
of
Dermatology
Department
at
Wake
Forest
University;
Adjunct
Professor
of
Dermatology
at
the
Weill
Cornell
School
of
Medicine.
Wake
Forest
University
Department
of
Dermatology
Wendy
E.
Roberts,
MD,
FAAD
Owner
Desert
Dermatology
Skin
Institute;
Founding
Director
of
Dermatopathology
of
Loma
Linda
Division
of
Dermatology.
Desert
Dermatology
Skin
Institute
Rancho
Mirage,
CA
James
Spencer,
MD,
MS
Director,
Spencer
Dermatology
&
Skin
Surgery
Center;
Professor
of
Clinical
Dermatology.
Spencer
Dermatology
&
Skin
Surgery
Center
St.
Petersburg,
FL
Heidi
A.
Waldorf,
MD
Director,
Laser
and
Cosmetic
Dermatology
Associate
Clinical
Professor,
Department
of
Dermatology.
Mount
Sinai
Medical
Center
New
York,
NY

22.
21
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Name
Title
/
Expertise
Organization
/
Location
Chiming
Wei,
MD,
PhD
Director,
Cardiothoracic-­‐Renal
Nanomedicine
Program;
Chairman
of
AANM;
Editor-­‐in-­‐Chief,
NANOMEDICINE,
and
Journal
of
Cardiothoracic-­‐
Renal
Research;
Leader
in
Global
Healthcare
Technology
Products
and
Platforms
Markets
Leaders
in
Global
Healthcare
Technology
Products
and
Platforms
Markets
Christopher
J.
Elias,
MD,
MPH
President
and
CEO;
Emerging
technologies
which
address
global
health
problems
CEO
of
Global
and
National
Healthcare
Technology
Company
Donald
W
Rucker,
MD,
MBA,
MS
Clinical
Assistant
Professor
of
Emergency
Medicine;
Vice
President
and
Chief
Medical
Officer.
Siemens
Medical
Solutions
Telemedicine
&
eHealth
Dr.
Adriano
Cavalcanti
Medical
nanorobotics
inventor
for
practical
hardware
architecture
of
nanorobots;
Nanorobotics
pioneer,
Chairman
and
CEO
of
CAN
Center
for
Automation
in
Nanobiotech
Academic
Thought
Leader
in
Global
Healthcare
Technology
Products
and
Platforms
Markets
METHODOLOGY
Questionnaire
Table
3:
Examples
of
Potential
Questions
for
KOLs
1.) What
do
you
believe
are
the
areas
of
greatest
growth
in
Advanced
Wound
Care
technologies
and
therapies
over
the
Mid-­‐Term?
Do
these
differ
in
Europe?
Globally?
2.) How
do
you
believe
these
will
be
manifested?
In
Europe?
Globally?
3.) What
factors
would
you
define
as
essential
to
leveraging
these
new
technologies
and
therapies,
particularly
over
the
Mid-­‐Term?
Do
these
differ
in
Europe?
Globally?
4.) What
do
you
see
as
the
major
macro
trends
influencing
patient
and
physician
acceptance,
and
reimbursement
in
the
introduction
of
new
Advanced
Wound
Care
technologies
or
therapies,
particularly
over
the
Mid-­‐Term?
Do
these
differ
in
Europe?
Globally?
5.) Which
of
these
trends
do
you
believe
will
have
the
greatest
impact
in
the
Mid-­‐Term
future?
In
Europe?
Globally?
6.) What
do
you
see
as
the
major
macro
trends
influencing
patient
and
physician
acceptance,
and
reimbursement
in
the
establishment
of
Advanced
Wound
Care
technologies
or

23.
22
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
therapies
as
the
Standard
of
Care,
particularly
over
the
Mid-­‐Term?
Do
these
differ
in
Europe?
Globally?
7.) Which
of
these
trends
do
you
believe
will
have
the
greatest
impact
in
the
Mid-­‐Term?
In
Europe?
Globally?
8.) Which
specific
methodologies
are
you
currently
promoting/
researching
/
developing
and
why?
Do
these
differ
in
Europe?
Globally?
9.) What
or
who
has
driven
change
in
Advanced
Wound
Care
technologies
and
therapies?
In
Europe?
Globally?
10.) Which
changes
have
been
the
most
problematic
to
achieve?
In
Europe?
Globally?
11.) What
issues
in
regulatory
affairs
are
specific
to
Advanced
Wound
Care
technologies
and
therapies?
Do
these
differ
in
Europe?
Globally?
12.) What
issues
in
physician
acceptance
are
specific
to
the
Mid-­‐
Term
market
development
for
Advanced
Wound
Care
technologies?
Do
these
differ
in
Europe?
Globally?
13.) What
are
the
most
effective
methodologies
to
use
to
leverage
Advanced
Wound
Care
adjacencies
particularly
over
the
Mid-­‐Term?
In
Europe?
Globally?
14.) What
factors
are
the
most
problematic
in
the
development
of
new
Advanced
Wound
Care
technologies?
How
do
you
address
those
factors?
In
Europe?
Globally?
METHODOLOGY
Secondary
Research
Harrison
Hayes
has
an
extensive
proprietary
database
of
secondary
research
that
will
add
exceptional
value
to
obtaining
a
complete
understanding
of
key
methods
in
leveraging
current
and
future
Advanced
Wound
Care
technologies
and
therapies
that
are
compatible
with
CLIENT
X’s
core
competencies
both
in
Europe
and
globally,
and
with
a
focus
on
the
Mid-­‐Term.
Harrison
Hayes
will
provide
a
thorough
ideation
of
whitespace
opportunities
within
core
adjacencies
of
all
Advanced
Wound
Care
Management
ecosystems
for
CLIENT
X
in
order
to
chart
out
pathways,
timelines
and
capabilities
with
newly
ideated
technologies
and
therapies,
including
market
outlook,
profitability,
national
and
international
policy
outlook,
technology
development
and
utilization,
market
entry
and
expansion
timing,
launch
strategy,
and
expansion
method.
Subsequent
content
will
provide
some
interesting
findings
uncovered
from
preliminary
secondary
research.

24.
23
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
Syndicated
Harrison
Hayes
has
established
relationships
with
a
variety
of
syndicated
information
providers
within
the
Advanced
Wound
Care
Management
technology,
medical,
and
biotechnology
fields
particularly,
but
not
exclusively,
in
Europe
that
are
complementary
to
the
core
adjacencies
of
CLIENT
X’s
current
business
portfolio.
Publicly
Available
Harrison
Hayes
conducts
significant
market
research
within
the
public
domain.
We
have
expertise
in
identifying
key
data
through
journal
and
trade
publications,
online
subscription
databases,
Advanced
Wound
Care
Management
technology
and
therapy
research
data
hubs,
proprietary
data
sources
and
archival
research.
Internal
One
of
Harrison
Hayes’s
key
assets
is
the
research
previously
conducted
that
resides
“in-­‐house”.
Our
ability
to
leverage
this
data
significantly
reduces
the
time
constraints
associated
with
providing
the
required
deliverables.
TRENDSPOTTING
Trendspotting
is
a
form
of
trending
analysis
focused
on
identifying
unmet
needs
and
emerging
opportunities
that
may
provide
near-­‐term
and
intermediate-­‐term
value
generation
within
one
or
more
of
the
Advanced
Wound
Care
Management
technologies
and
therapies.
Trending
analysis
that
is
focused
on
identifying
the
potential
of
leveraging
current
and
future
Advanced
Wound
Care
Management
technologies
and
therapies
that
are
compatible
with
CLIENT
X’s
core
competencies
particularly,
but
not
exclusively,
in
Europe,
requires
primary
and
secondary
research
to
uncover
emerging
patterns
and
useful
data.
We
do
not
guess
trends;
we
detect,
analyze
and
evaluate
them
to
make
evidentially
supported
projections.
For
this
project,
our
challenge
is
to
determine
the
useful
data
regarding
the
potential
of
leveraging
current
and
future
Advanced
Wound
Care
technologies
and
therapies
that
are
compatible
with
CLIENT
X’s
core
competencies
particularly,
but
not
exclusively,
in
Europe
and
have
significant
potential
for
return
on
investment.
Because
CLIENT
X’s
KOLs
have
significant
insight
into
the
current
state
of
Advanced
Wound
Care
Management
technologies
and
therapies
in
Europe
and
globally,
they
are
on
the
cutting
edge
of
trends
and
function
as
valuable
resource
for
understanding
real-­‐world
process
evaluation
and
improvement.
Examples
of
trends
that
we
would
like
to
uncover
include:

25.
24
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
• Cutting
edge
approaches
and
new
technologies
which
identify
the
potential
of
leveraging
Advanced
Wound
Care
Management
technologies
and
therapies
particularly,
but
not
exclusively,
in
Europe,
that
are
compatible
with
CLIENT
X’s
core
competencies
• Future
trends
influencing
Advanced
Wound
Care
Management
technologies
and
therapies
particularly,
but
not
exclusively,
in
Europe,
that
are
compatible
with
CLIENT
X’s
core
competencies
• Changing
trends
in
Advanced
Wound
Care
Management
technology
and
therapy
regulatory
policy
particularly,
but
not
exclusively,
in
Europe
Trending
research
is
an
integral
part
of
a
successful
research
initiative,
and
Harrison
Hayes
is
confident
our
trend
spotting
methods
will
afford
CLIENT
X
the
necessary
insight
on
industry
dynamics
particularly,
but
not
exclusively,
in
Europe
regarding
the
identification
of
current
and
near-­‐
to
mid-­‐term
Advanced
Wound
Care
Management
technologies
and
therapies
that
are
compatible
with
CLIENT
X’s
core
competencies.

26.
25
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
FINAL
REPORT
Our
final
deliverable
for
this
project
is
an
Internalized
Strategy
Report(“Strataject
Report™”).
The
Strataject
Report™
is
the
culmination
of
all
primary
and
secondary
research
and
activities,
which
have
taken
place
over
the
duration
of
the
engagement.
This
report
serves
as
an
action
plan
illustrating
the
information
that
will
afford
CLIENT
X
the
necessary
insight
on
customer
industry
dynamics
regarding
identification
of
unmet
needs
and
emerging
opportunities
in
order
to
leverage
current
and
mid-­‐term
Advanced
Wound
Care
Management
technologies
and
therapies
particularly,
but
not
exclusively,
in
Europe
that
are
compatible
with
CLIENT
X’s
core
competencies.
Harrison
Hayes
will
provide
a
thorough
review
of
the
European
and
Global
Advanced
Wound
Care
Management
Markets
including
internal
and
external
drivers
and
inhibitors,
and
a
review
of
the
business
issues,
barriers
and
challenges
of
the
current
markets
in
order
to
understand
those
new
and
emerging
opportunities
that
may
provide
near-­‐term
and
intermediate-­‐term
value
generation.
Harrison
Hayes
will
make
recommendation
of
core
competency
compatible
adjacencies
with
a
particular
but
not
exclusive
focus
on
Europe
that
can
be
leveraged
for
near-­‐term
and
intermediate-­‐term
value
generation.
Harrison
Hayes
will
also
make
recommendation
of
strategies
to
leverage
patient
and
physician
acceptance,
and
reimbursement,
of
current
and
innovative
technologies
and
therapies
in
the
European
and
Global
Advanced
Wound
Care
Management
Market.
Harrison
Hayes
will
schedule
a
time
to
present
and
discuss
our
findings
and
recommendations
to
CLIENT
X.
During
this
meeting
we
will
discuss
in
detail
our
front-­‐end
research,
our
findings,
and
our
recommendations
for
CLIENT
X
including
areas
of
areas
of
highest
relevance
for
identification
and
leveraging
of
unmet
needs
and
emerging
opportunities
within
the
Advanced
Wound
Care
Management
technologies
and
therapies
with
a
particular
but
not
exclusive
focus
on
Europe.
Harrison
Hayes
will
also
provide
a
thorough
review
of
market
drivers
and
inhibitors,
an
analysis
of
critical
success
factors,
identification
and
detailed
assessment
of
the
opportunities
and
challenges,
and
an
evaluation
of
near-­‐term
and
intermediate-­‐term
value
generation
including
revenue
generation
and
expected
return
on
investment
within
the
European
and
global
Advanced
Wound
Care
Management
Market.

27.
26
CLIENT
X
-­‐
Whitespace
Ideation
Study:
Mid
Term
Opportunities
Within
Wound
Care
-­‐
Confidential
PRICING
&
TIMELINE
Terms:
50%
due
upon
inception
of
project
and
50%
due
within
30
days
of
inception.
Travel
expenses
will
be
billed
at
cost.
CLIENT
X
will
approve
all
travel
expense
prior
to
incurring
any
costs.
CLIENT
X,
PLC
Harrison
Hayes,
LLC
Signature:
_________________________
Signature:
_________________________
Name:
_____________________________
Name:
_____________________________
Title:
______________________________
Title:
_______________________________
Date:
______________________________
Date:
_______________________________
Activity
Weeks
Fee
25
KIL
Interviews
Ideation
Concept/Validation
Research
Total
Project
Duration
and
Fee